Literature DB >> 11992123

Suppression of the p53- or pRB-mediated G1 checkpoint is required for E2F-induced S-phase entry.

Marina Lomazzi1, M Cristina Moroni, Michael R Jensen, Emanuela Frittoli, Kristian Helin.   

Abstract

Deregulation of the retinoblastoma protein (pRB) pathway is a hallmark of cancer. In the absence of other genetic alterations, this deregulation results in lack of differentiation, hyperproliferation and apoptosis. The pRB protein acts as a transcriptional repressor by targeting the E2F transcription factors, whose functions are required for entry into S phase. Increased E2F activity can induce S phase in quiescent cells--this is a central element of most models for the development of cancer. We show that although E2F1 alone is not sufficient to induce S phase in diploid mouse and human fibroblasts, increased E2F1 activity can result in S-phase entry in diploid fibroblasts in which the p53-mediated G1 checkpoint is suppressed. In addition, we show that E2F1 can induce S phase in primary mouse fibroblasts lacking pRB. These results indicate that, in addition to acting as an E2F-dependent transcriptional repressor, pRB is also required for the cells to retain the G1 checkpoint in response to unprogrammed proliferative signals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992123     DOI: 10.1038/ng891

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  27 in total

1.  E2F7, a novel E2F featuring DP-independent repression of a subset of E2F-regulated genes.

Authors:  Luisa Di Stefano; Michael Rugaard Jensen; Kristian Helin
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

2.  DNA damage signals through differentially modified E2F1 molecules to induce apoptosis.

Authors:  Jasmyne Carnevale; Oliva Palander; Laurie A Seifried; Frederick A Dick
Journal:  Mol Cell Biol       Date:  2011-12-19       Impact factor: 4.272

3.  Distinct E2F-mediated transcriptional program regulates p14ARF gene expression.

Authors:  Hideyuki Komori; Mitsuru Enomoto; Masataka Nakamura; Ritsuko Iwanaga; Kiyoshi Ohtani
Journal:  EMBO J       Date:  2005-10-06       Impact factor: 11.598

4.  Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland.

Authors:  Eros Lazzerini Denchi; Claire Attwooll; Diego Pasini; Kristian Helin
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

5.  Ectopic expression of E2F1 stimulates beta-cell proliferation and function.

Authors:  Gael Grouwels; Ying Cai; Inge Hoebeke; Gunter Leuckx; Yves Heremans; Ulrike Ziebold; Geert Stangé; Marie Chintinne; Zhidong Ling; Daniel Pipeleers; Harry Heimberg; Mark Van de Casteele
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

6.  E2F1 plays a direct role in Rb stabilization and p53-independent tumor suppression.

Authors:  Gustavo Palacios; Flaminia Talos; Alice Nemajerova; Ute M Moll; Oleksi Petrenko
Journal:  Cell Cycle       Date:  2008-06-30       Impact factor: 4.534

7.  MiR-351 transiently increases during muscle regeneration and promotes progenitor cell proliferation and survival upon differentiation.

Authors:  Yongxin Chen; David W Melton; Jonathan A L Gelfond; Linda M McManus; Paula K Shireman
Journal:  Physiol Genomics       Date:  2012-09-11       Impact factor: 3.107

Review 8.  Somatic TP53 Mutations in the Era of Genome Sequencing.

Authors:  Pierre Hainaut; Gerd P Pfeifer
Journal:  Cold Spring Harb Perspect Med       Date:  2016-11-01       Impact factor: 6.915

9.  INMAP, a novel truncated version of POLR3B, represses AP-1 and p53 transcriptional activity.

Authors:  Zhou Yunlei; Chen Zhe; Lei Yan; Wang Pengcheng; Zheng Yanbo; Sun Le; Liang Qianjin
Journal:  Mol Cell Biochem       Date:  2012-11-04       Impact factor: 3.396

Review 10.  Melanomagenesis: overcoming the barrier of melanocyte senescence.

Authors:  Linan Ha; Glenn Merlino; Elena V Sviderskaya
Journal:  Cell Cycle       Date:  2008-04-23       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.